Fastest
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →https://www.patsnap.com/resources/blog/rd-blog/stem-cell-technology-patent-landscape-patent-landscape/ · Patsnap · data cut-off 2026-08-31 · downloaded from the live page
Patent Landscape · Stem-Cell TechnologyStem-Cell Technology Patents: Filing Trends and Where the Field Is Still Open
- Leadership is diffuse. the ranked leader holds 11,564 records but the top 10 assignees combined account for just 14.8% of all 300,246 records in scope — a long tail dominates.
- Filings have cooled from their 2018 peak. annual output ran from 741 records at peak down to 352 by 2024, a -33% move over 2021-2024, though the two most recent years are still filling in under publication lag.
- Claim density is concentrated in a few subclasses. A61K and C12N each cover roughly 4.5% of all records, while classes like C07H sugars and nucleic acids sit under 1% — a sign of where occupied ground ends.
300.2K
Published Records
10%
Top-5 Share of All Records
-33%
Filing Growth 2021→2024
US
Leading Jurisdiction
Filing growth compares 2021 (528 records) with 2024 (352) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 300,246 records in scope (CR5), not by the ranked leaders only.
Published byPatsnap Research··7 min readSourced from Patsnap Eureka
Field Overview
What the stem-cell patent corpus actually covers
The corpus in scope combines core stem-cell terminology with adjacent functional language — differentiation marker, molecular scaffold, tissue regeneration, screening assay and drug candidate — which pulls in both the biology of stem-cell derivation and the downstream applications built on it: therapeutics, regenerative scaffolds, and assay platforms used to validate drug candidates against stem-cell-derived tissue models. That breadth is why the record count runs into the hundreds of thousands rather than the tens of thousands typical of a narrower cell-therapy search.
Reading this landscape by patent family rather than raw publication count matters here, because continuation practice and multi-jurisdiction filing inflate document counts without adding new invention. The filing trend, assignee ranking and IPC composition below are all built on that more conservative basis.
Filing activity and technology composition, 2015 to the 2026 cut-off
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Stem-Cell Technology Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
The Data
Filing trend and technology composition
Two views of the same 300,246-record corpus: how filing volume has moved year over year, and how records distribute across IPC subclasses. Because a single record can carry several IPC codes, the class shares below sum to more than the record total — that is expected and not an error.
Filing trend, 2017-2026
Filings ran from 679 records in 2017 to a peak of 741 in 2018, then eased to 352 by 2024 — a -33% move over 2021-2024. 2025 and 2026 show far lower counts (27 in 2026) but that reflects publication lag of roughly 18 months rather than a genuine drop in filing activity; treat the last two years as incomplete.
Technology composition by IPC subclass
A61K (medicinal preparations) and C12N (microorganisms and genetic engineering) are the two largest subclasses, each near 4.5% of all records. C07K peptides and proteins follows at 3.0%. Assay and measurement classes — G01N and C12Q — sit near 1.6-1.7%, and C07H sugars and nucleic acids is under 1%, marking the thinnest-claimed subclass in this set.
Shares are the percentage of the 300,246 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Stem-Cell Technology Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.
Go deeper on Stem-Cell Technology Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about stem-cell technology patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaKey Patents
The most-cited records in the corpus
Representative Filing
Method for in vitro detection of the proarrhythmogenic risk of a drug candidate on hiPSC-derived cardiomyocytes
UNIVERSITATEA DIN BUCURESTI
This filing describes an in vitro method for detecting the proarrhythmogenic risk of a drug candidate using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM). Ion currents and externally paced action potentials are measured on an automated patch-clamp platform before and after drug application, and a cardiomyocyte electrophysiology model reproduces the paced action-potential shape to generate a restoration stimulus reflecting the ion currents inhibited by the candidate compound.Filed by a university assignee rather than a pharmaceutical major — illustrative of how academic groups contribute cardiac-safety assay methods into this space.
Highest-citation records
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2001075067A2 | Novel nucleic acids and polypeptides | 973 |
| 2 | WO2001077137A1 | Albumin fusion proteins | 811 |
| 3 | US9101621B2 | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione a… | 775 |
| 4 | US5811094A | Connective tissue regeneration using human mesenchymal stem cell preparations | 768 |
| 5 | US20050100543A1 | Multivalent carriers of bi-specific antibodies | 728 |
| 6 | US20060019256A1 | Compositions and methods for treating and diagnosing cancer | 692 |
| 7 | US5736396A | Lineage-directed induction of human mesenchymal stem cell differentiation | 667 |
| 8 | WO2001040309A2 | Anti-prostate stem cell antigen (PSCA) antibody compositions and methods of use | 589 |
| 9 | WO1997007198A2 | DNA sequences and secreted proteins encoded thereby | 575 |
| 10 | WO2009007852A2 | Multipotent/pluripotent cells and methods | 567 |
Citation counts inside a searched corpus skew toward older filings simply because they have had more time to accumulate citations — read them as a signal of influence on the field, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Stem-Cell Technology Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself
Put your own technology through the same analysis
Where to run it
For builders
MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Insights
What the numbers say about the field
Three patterns stand out once filing volume, assignee concentration and citation data are set side by side.
Concentration
14.8%
of 300,246 records held by top 10 assignees
No single owner controls the field
The leading assignee holds 11,564 records, but the top 5 combined account for only 9.7% of all records in scope and the top 10 for 14.8%. That is a wide base rather than a chokepoint — freedom-to-operate analysis has to look past any one filer.
Based on the 100-company ranked assignee list.
Momentum
-33%
change in annual filings, 2021 to 2024
Filing pace has eased from its 2018 peak
Annual filings peaked at 741 in 2018 and had fallen to 352 by 2024, a -33% move over that three-year span. The 2025-2026 figures look much lower still, but that is the expected effect of publication lag, not a real collapse in activity.
2024 is the most recent year treated as complete.
Claim density
4.6%
of records classed under A61K
Medicinal preparations and genetic engineering carry the heaviest claim load
A61K and C12N each sit near 4.5% of all 300,246 records, well ahead of assay-related classes like G01N and C12Q near 1.6-1.7%. New filings aimed squarely at medicinal-preparation claims are entering the most contested ground in the corpus.
Class shares sum above 100% because records carry multiple IPC codes.
Citation influence
973 citations
highest count in the corpus
The most-cited records are early, broad filings
The top-cited records include broad nucleic-acid and fusion-protein filings from the early 2000s alongside a mesenchymal stem cell tissue-regeneration patent — these are foundational documents, not necessarily the ones defining current freedom-to-operate.
Citation counts favour older filings within the searched corpus.
Eureka AI Agent
Looking for what nobody has claimed yet?
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to stem-cell technology patent landscape, with the prior art for and against each one.
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Stem-Cell Technology Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Players
Who is filing, and where the openings sit
The assignee ranking spans 100 companies and research institutions, counted by patent family. Ownership is spread widely enough that no single filer defines the field, which changes how a new entrant should read the competitive map.
Leader
11,564 records
held by the top-ranked assignee
One clear leader, then a broad field
The leading assignee's 11,564 records dwarf the fifth-place figure of 3,470, but from there the ranking flattens quickly — tenth place holds 2,905. The drop-off after the leader is sharp rather than gradual.
Ranked by patent family count.
Long tail
100 companies
in the full ranked list
A long tail of single-digit filers
Beyond the leading names, the ranked list runs through universities, government research bodies and mid-size biotech filers, none holding a dominant share. This is a field where a well-targeted filing can still stake meaningful ground.
Ranking covers the complete 100-company list returned by the data endpoint.
Collaboration
10 pairs
co-assignee pairings identified
A small set of recurring co-filing relationships
Only 10 co-assignee pairs appear in the data, the strongest linking two named inventors at 359 shared records. Collaborative filing is the exception here, not the norm — most records carry a single assignee.
Strongest pair drawn from the co-assignee data.
Recent-year filing momentum by assignee
| Assignee | Recent year | YoY |
|---|---|---|
| Genentech Inc. | 0 | — |
| Human Genome Sciences, Inc. | 0 | — |
| CURAGEN CORP | 0 | — |
| Millennium Pharmaceuticals, Inc. | 0 | — |
| ROSEN CRAIG A | 0 | — |
| Hyseq Inc. | 0 | — |
| Genetics Institute, LLC | 0 | — |
| RUBEN STEVEN M | 0 | — |
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Stem-Cell Technology Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's Next
Where to take this analysis
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, portfolio strategy or identifying acquisition targets.
Map claim scope against the thinnest IPC classes
C07H and C12P carry the lowest record shares in this corpus — a detailed claim-by-claim read of what little prior art exists there shows whether a new filing has real room.
Explore white space in Eureka →Track the leader's recent filing behaviour
A large historical lead does not guarantee current momentum; checking recent-year filing counts against the historical total shows whether a leader is still active or coasting on an old portfolio.
Run assignee momentum in Eureka →Read the most-cited filings as foundational, not final
The highest-citation records date from the early 2000s. Current freedom-to-operate work needs a citation-independent read of filings from the last three to five complete years.
Search recent filings in Eureka →Source: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Stem-Cell Technology Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ
Common questions about the stem-cell patent landscape
The ranked assignee list covers 100 companies and institutions, with the leading assignee holding 11,564 records — well ahead of the fifth-place holder at 3,470. That said, the top 10 assignees combined account for only 14.8% of all 300,246 records in scope, so no single organisation controls the field. A freedom-to-operate review needs to look well beyond the leading names.
Annual filings peaked at 741 records in 2018 and had eased to 352 by 2024, a -33% change over the 2021-2024 span. The 2025 and 2026 figures look much lower still, but that reflects publication lag of roughly 18 months rather than an actual drop in filing behaviour — those most recent years should not be read as a decline.
A61K (medicinal preparations) and C12N (microorganisms and genetic engineering) are the largest, each covering roughly 4.5% of all 300,246 records in scope. C07K peptides and proteins follows at 3.0%. Because records often carry multiple IPC codes, these shares sum to more than 100% of the corpus, which is expected.
The IPC classes with the lowest record shares — C07H sugars and nucleic acids under 1%, and C12P fermentation and enzymatic synthesis at 1.0% — show the thinnest claim density in this corpus. Assay-related classes like G01N and C12Q also sit well below the medicinal-preparation core near 1.6-1.7%. These lower-density branches are where a well-drafted new claim has more room to stand without colliding with dense prior art.
The most-cited records in this corpus date largely from the early 2000s, including broad nucleic-acid and fusion-protein filings alongside a foundational mesenchymal stem cell tissue-regeneration patent. High citation counts inside a searched corpus favour older filings simply because they have had longer to accumulate citations, so treat them as a marker of historical influence rather than current commercial relevance or validity strength.
Answers are grounded in the same dataset. Derived from a Patsnap search on Stem-Cell Technology Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Research Stem-Cell Technology Patent Landscape in depth with Eureka
Go past this page: query the whole stem-cell technology patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.